
RMD
Resmed Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
278.860
Open
273.345
VWAP
--
Vol
1.71M
Mkt Cap
40.68B
Low
271.640
Amount
--
EV/EBITDA(TTM)
22.23
Total Shares
146.91M
EV
40.46B
EV/OCF(TTM)
24.48
P/S(TTM)
8.15
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
1.39B
+8.38%
2.620
+7.82%
1.32B
+8.04%
2.449
+11.3%
1.33B
+8.78%
2.467
+18.59%
Estimates Revision
The market is revising Upward the revenue expectations for ResMed Inc. (RMD) for FY2025, with the revenue forecasts being adjusted by 0.05% over the past three months. During the same period, the stock price has changed by 17.27%.
Revenue Estimates for FY2025
Revise Upward

+0.05%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+0.09%
In Past 3 Month
Stock Price
Go Up

+17.27%
In Past 3 Month
14 Analyst Rating

-0.88% Downside
Wall Street analysts forecast RMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RMD is 275.00 USD with a low forecast of 240.00 USD and a high forecast of 294.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
5 Hold
0 Sell
Moderate Buy

-0.88% Downside
Current: 277.440

Low
240.00
Averages
275.00
High
294.00

-0.88% Downside
Current: 277.440

Low
240.00
Averages
275.00
High
294.00
RBC Capital
Craig Wong-Pan
Sector Perform -> Outperform
upgrade
$255 -> $294
2025-07-16
Reason
RBC Capital
Craig Wong-Pan
Price Target
$255 -> $294
2025-07-16
upgrade
Sector Perform -> Outperform
Reason
RBC Capital analyst Craig Wong-Pan upgraded ResMed to Outperform from Sector Perform with a price target of $294, up from $255. The firm expects the company to report solid fiscal 2025 results with a positive outlook for fiscal 2026. In addition, the stock's valuation is "undemanding" while ResMed "offers a safe haven from tariffs," the analyst tells investors in a research note.
Mizuho
Anthony Petrone
Outperform
maintain
$250 -> $270
2025-07-16
Reason
Mizuho
Anthony Petrone
Price Target
$250 -> $270
2025-07-16
maintain
Outperform
Reason
Mizuho analyst Anthony Petrone raised the firm's price target on ResMed to $270 from $250 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Morgan Stanley
David Bailey
Overweight
maintain
$286
2025-05-20
Reason
Morgan Stanley
David Bailey
Price Target
$286
2025-05-20
maintain
Overweight
Reason
Morgan Stanley analyst David Bailey keeps an Overweight rating on ResMed with a $286 price target after Apnimed provided topline results as part of its Phase 3 trial for AD109, focused on the treatment of obstructive sleep apnea. Participants treated with AD109 recorded a mean Apnea-Hypopnea Index reduction of 55.6% from baseline, the analyst tells investors in a research note. The firm believes AD109 appears to focus on patients who are unable or refuse to tolerate continuous positive airway pressure, or CPAP. Further, patients who record an AHI less than 10 appear to be those with mild to moderate sleep apnea, the analyst tells investors in a research note. On balance, Morgan Stanley sees a "modest" potential earnings impact for ResMed based on current data from Apnimed.
KeyBanc
Brett Fishbin
Overweight
maintain
$269 -> $274
2025-04-24
Reason
KeyBanc
Brett Fishbin
Price Target
$269 -> $274
2025-04-24
maintain
Overweight
Reason
KeyBanc analyst Brett Fishbin raised the firm's price target on ResMed to $274 from $269 on higher estimates, while keeping an Overweight rating on the shares. The firm believes investors will view ResMed's Q3 release and call favorably, given solid results and definitively positive commentary on potential tariff exposure.
RBC Capital
Sector Perform
maintain
$247 -> $255
2025-04-24
Reason
RBC Capital
Price Target
$247 -> $255
2025-04-24
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on ResMed to $255 from $247 and keeps a Sector Perform rating on the shares. The company's Q3 result showed ongoing solid growth in revenue and earnings, and while they were in line with market expectations, a positive update was that the company's products should continue to be largely exempt from U.S. import tariffs, the analyst tells investors in a research note.
Mizuho
Outperform
to
NULL
downgrade
$265 -> $250
2025-04-24
Reason
Mizuho
Price Target
$265 -> $250
2025-04-24
downgrade
Outperform
to
NULL
Reason
Mizuho lowered the firm's price target on ResMed to $250 from $265 and keeps an Outperform rating on the shares. The company reported in-line fiscal Q3 results and sees little to no tariff impact, the analyst tells investors in a research note. The firm says ResMed is "on right side of tariff equation" and there is no evidence of GLP-1 cannibalization.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Resmed Inc (RMD.N) is 27.30, compared to its 5-year average forward P/E of 31.04. For a more detailed relative valuation and DCF analysis to assess Resmed Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair
5Y Average PE
31.04
Current PE
27.30
Overvalued PE
39.08
Undervalued PE
23.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair
5Y Average EV/EBITDA
22.83
Current EV/EBITDA
19.82
Overvalued EV/EBITDA
27.85
Undervalued EV/EBITDA
17.80
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
7.57
Current PS
7.47
Overvalued PS
9.18
Undervalued PS
5.96
Financials
Annual
Quarterly
FY2025Q3
YoY :
+7.92%
1.29B
Total Revenue
FY2025Q3
YoY :
+13.80%
426.27M
Operating Profit
FY2025Q3
YoY :
+21.48%
365.04M
Net Income after Tax
FY2025Q3
YoY :
+21.57%
2.48
EPS - Diluted
FY2025Q3
YoY :
+46.43%
554.87M
Free Cash Flow
FY2025Q3
YoY :
+2.72%
58.49
Gross Profit Margin - %
FY2025Q3
YoY :
+32.91%
31.06
FCF Margin - %
FY2025Q3
YoY :
+12.59%
28.26
Net Margin - %
FY2025Q3
YoY :
+28.93%
22.15
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
9.9M
USD
12
3-6
Months
9.4M
USD
10
6-9
Months
10.7M
USD
17
0-12
Months
13.3M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
800.0
Volume
1
6-9
Months
70.2K
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
16.6K
Volume
Months
6-9
2
928.6K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
16.0K
USD
2
3-6
Months
16.0K
USD
2
6-9
Months
8.0K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
8.0K
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
9.9M
USD
12
3-6
Months
9.4M
USD
10
6-9
Months
10.7M
USD
17
0-12
Months
13.3M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
RMD News & Events
Events Timeline
2025-07-23 (ET)
2025-07-23
15:05:45
Apnimed says sleep apnea drug meets primary endpoint in Phase 3 trial

2025-05-20 (ET)
2025-05-20
09:49:40
Apnimed data brings competitive threat to ResMed, says RBC Capital

2025-05-15 (ET)
2025-05-15
09:06:21
ResMed named Sleep Partner of the Qatar Airways British & Irish Lions Tour

Sign Up For More Events
Sign Up For More Events
News
4.0
07-16BenzingaMizuho Maintains Outperform on ResMed, Raises Price Target to $270
9.5
07-01NewsfilterResmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025
6.5
06-26NASDAQ.COMZacks.com featured highlights Sprouts Farmers Market, Adobe, GE Aerospace and ResMed
Sign Up For More News
People Also Watch

HUM
Humana Inc
261.470
USD
+12.40%

WAB
Westinghouse Air Brake Technologies Corp
190.640
USD
-1.11%

ED
Consolidated Edison Inc
102.590
USD
+0.34%

RJF
Raymond James Financial Inc
169.460
USD
+0.86%

ETR
Entergy Corp
89.290
USD
+1.19%

IMO
Imperial Oil Ltd
84.300
USD
-1.61%

LEN
Lennar Corp
112.370
USD
-3.01%

MLM
Martin Marietta Materials Inc
575.320
USD
-0.79%

VEEV
Veeva Systems Inc
286.900
USD
-0.11%

SLF
Sun Life Financial Inc
61.190
USD
-1.37%
FAQ

What is Resmed Inc (RMD) stock price today?
The current price of RMD is 277.44 USD — it has decreased -0.09 % in the last trading day.

What is Resmed Inc (RMD)'s business?

What is the price predicton of RMD Stock?

What is Resmed Inc (RMD)'s revenue for the last quarter?

What is Resmed Inc (RMD)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Resmed Inc (RMD)'s fundamentals?

How many employees does Resmed Inc (RMD). have?
